Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.
Shlobin OA, Shen E, Wort SJ, Piccari L, Scandurra JA, Hassoun PM, Nikkho SM, Nathan SD. Shlobin OA, et al. Among authors: nikkho sm. Pulm Circ. 2024 Jan 10;14(1):e12310. doi: 10.1002/pul2.12310. eCollection 2024 Jan. Pulm Circ. 2024. PMID: 38205098 Free PMC article. Review.
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.
Nikkho SM, Richter MJ, Shen E, Abman SH, Antoniou K, Chung J, Fernandes P, Hassoun P, Lazarus HM, Olschewski H, Piccari L, Psotka M, Saggar R, Shlobin OA, Stockbridge N, Vitulo P, Vizza CD, Wort SJ, Nathan SD. Nikkho SM, et al. Pulm Circ. 2022 Jul 1;12(3):e12127. doi: 10.1002/pul2.12127. eCollection 2022 Jul. Pulm Circ. 2022. PMID: 36016668 Free PMC article. Review.
Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.
Nathan SD, Fernandes P, Psotka M, Vitulo P, Piccari L, Antoniou K, Nikkho SM, Stockbridge N. Nathan SD, et al. Among authors: nikkho sm. Pulm Circ. 2022 Oct 1;12(4):e12178. doi: 10.1002/pul2.12178. eCollection 2022 Oct. Pulm Circ. 2022. PMID: 36578976 Free PMC article. Review.
Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension.
Piccari L, Allwood B, Antoniou K, Chung JH, Hassoun PM, Nikkho SM, Saggar R, Shlobin OA, Vitulo P, Nathan SD, Wort SJ. Piccari L, et al. Among authors: nikkho sm. Pulm Circ. 2023 Apr 1;13(2):e12213. doi: 10.1002/pul2.12213. eCollection 2023 Apr. Pulm Circ. 2023. PMID: 37025209 Free PMC article. Review.
Updating clinical endpoint definitions.
Hassoun PM, Nikkho S, Rosenzweig EB, Moreschi G, Lawrence J, Teeter J, Meier C, Ghofrani AH, Minai O, Rinaldi P, Michelakis E, Oudiz RJ. Hassoun PM, et al. Pulm Circ. 2013 Jan;3(1):206-16. doi: 10.4103/2045-8932.109920. Pulm Circ. 2013. PMID: 23662199 Free PMC article.
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study.
Nathan SD, Cottin V, Behr J, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Ley-Zaporozhan J, Müller-Lisse UG, Scholle FD, Brüggenwerth G, Busse D, Nikkho S, Wells AU. Nathan SD, et al. J Heart Lung Transplant. 2021 Jun;40(6):494-503. doi: 10.1016/j.healun.2021.02.006. Epub 2021 Feb 19. J Heart Lung Transplant. 2021. PMID: 33744088 Free article. Clinical Trial.
Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group.
Morland K, Gerges C, Elwing J, Visovatti SH, Weatherald J, Gillmeyer KR, Sahay S, Mathai SC, Boucly A, Williams PG, Harikrishnan S, Minty EP, Hobohm L, Jose A, Badagliacca R, Lau EMT, Jing ZC, Vanderpool RR, Fauvel C, Leonidas Alves J Jr, Strange G, Pulido T, Qian J, Li M, Mercurio V, Zelt JGE, Moles VM, Cirulis MM, Nikkho SM, Benza RL, Elliott CG. Morland K, et al. Among authors: nikkho sm. Pulm Circ. 2023 Dec 21;13(4):e12317. doi: 10.1002/pul2.12317. eCollection 2023 Oct. Pulm Circ. 2023. PMID: 38144948 Free PMC article.
27 results